

Resource Summary Report

Generated by NIF on Aug 10, 2026

Genomic Data Commons Data Portal (GDC Data Portal)

RRID:SCR_014514

Type: Tool

Proper Citation

Genomic Data Commons Data Portal (GDC Data Portal) (RRID:SCR_014514)

Resource Information

URL: <https://portal.gdc.cancer.gov/>

Proper Citation: Genomic Data Commons Data Portal (GDC Data Portal) (RRID:SCR_014514)

Description: A unified data repository of the National Cancer Institute (NCI)'s Genomic Data Commons (GDC) that enables data sharing across cancer genomic studies in support of precision medicine. The GDC supports several cancer genome programs at the NCI Center for Cancer Genomics (CCG), including The Cancer Genome Atlas (TCGA), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and the Cancer Genome Characterization Initiative (CGCI). The GDC Data Portal provides a platform for efficiently querying and downloading high quality and complete data. The GDC also provides a GDC Data Transfer Tool and a GDC API for programmatic access.

Synonyms: Genomic Data Commons Data Portal, GDC Data Portal

Resource Type: database, data or information resource

Keywords: genomics, data repository, portal, cancer, data sharing, cancer genomic studies

Related Condition: Cancer

Availability: Public, Available to the research community

Resource Name: Genomic Data Commons Data Portal (GDC Data Portal)

Resource ID: SCR_014514

Alternate IDs: r3d100012061

Old URLs: <https://gdc-portal.nci.nih.gov>

Record Creation Time: 20220129T080320+0000

Record Last Update: 20260808T190436+0000

Ratings and Alerts

No rating or validation information has been found for Genomic Data Commons Data Portal (GDC Data Portal).

No alerts have been found for Genomic Data Commons Data Portal (GDC Data Portal).

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 12118 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gupta I, et al. (2026) Correlation of the differential expression of PIK3R1 and its spliced variant, p55?, in pan-cancer. Molecular oncology, 20(5), 1299.

Cao B, et al. (2026) CGPA: A Multicontext Cancer Gene Prognosis Atlas. Molecular cancer research : MCR, 24(3), 188.

Hayward MK, et al. (2026) Tissue tension fosters macrophage-driven lipid peroxidation-induced DNA damage. Cancer cell, 44(6), 1255.

Maurencova D, et al. (2026) Cellular senescence escape and antiviral response discriminate glioblastoma from lower-grade gliomas. Neuro-oncology advances, 8(1), vdag122.

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. Cancer discovery, 16(1), 135.

Wang Y, et al. (2026) Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. Molecular cancer therapeutics, 25(6), 881.

Huang C, et al. (2026) Survival Genie 2: a next-generation web server for targeted and single-cell-based survival analyses. Genome medicine, 18(1).

Sherif S, et al. (2026) A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. Cancers, 18(9).

Aggrey-Fynn JE, et al. (2026) Epigenetic context defines the transcriptional activity of canonical and noncanonical NF-?B signaling in pancreatic cancer. Cell death discovery, 12(1).

Garg SK, et al. (2026) Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. *Cell reports*, 45(3), 117050.

Zhao W, et al. (2026) A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked. *Cancer discovery*, 16(3), 460.

Chen Y, et al. (2026) Suppressor of TCR signaling 2 (Sts-2) as a potential immunotherapy target and prognostic biomarker in cervical cancer. *Journal of gynecologic oncology*, 37(2), e20.

Wang Z, et al. (2026) Deciphering pathogenic mechanisms of BDCPP exposure in endometrial cancer progression via an integrated approach combining network toxicology, machine learning, and molecular docking. *International journal of surgery (London, England)*, 112(1), 583.

Li J, et al. (2026) FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. *Cancer research*, 86(2), 349.

Dela Cruz FS, et al. (2026) Advancing Preclinical Biology for Ewing Sarcoma: An International Effort. *Molecular cancer therapeutics*, 25(1), 48.

Jeong YJ, et al. (2026) USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics. *Asia-Pacific journal of clinical oncology*, 22(2), 260.

Zhu G, et al. (2026) Exploration Biomarkers for Recurrence of Hepatocellular Carcinoma After Liver Transplantation Based on Bioinformatics Analysis. *Biochemical genetics*, 64(3), 3896.

Tong H, et al. (2026) RBM11 drives malignant progression of bladder cancer by regulating GNPDA1-PKM2 axis. *iScience*, 29(4), 115402.

Tan B, et al. (2026) Identification of a Prognostic Gene Signature for Chemoresistance Prediction in Lung Adenocarcinoma by Screening Mitochondrial Metabolism Gene Sets. *International journal of molecular sciences*, 27(7).

Wu S, et al. (2026) Multi-omics analysis and experiments validate the tumor-suppressive role of mitochondrial lipid metabolism gene ACSM5 in lung adenocarcinoma and its impact on the immune microenvironment. *Human genomics*, 20(1).